Modulation of the Ca2+/Mg2+-ATPase Activity of Synaptosomal Plasma Membrane Vesicles by the Hypothalamic Hypophysary Na+/K+-ATPase Inhibitory Factor (HHIF)

  • M. Ricote
  • E. Garcia
  • C. Gutierrez
  • J. Sancho

Abstract

There is a general agreement that in essential hypertension there is a generalized alteration in membrane transport which leads to an increased peripheral resistance, decreased renal sodium excretion and plasma volume expansion (7). A circulating inhibitor of the sodium pump has been implicated in these three phenomena (3). The increased intracellular Ca2+ in vascular smooth muscle (VSM) cells is considered the final effect of the inhibitor leading to an increased contractility. It has also been speculated that this substances could be also be involved in the proliferation of VSM cells through the same mechanism. One of these factors is an endogenous compound first isolated from the hypothalamus and hypophysis, HHIF, (8) and later found to be present in other tissues although at lower concentrations (12) that has been shown to increase cell proliferation on rat mesangial cells (10). This nonpeptidic, nonlipidic Na*-pump inhibitor is different from any known cardioglycoside (12). Based in these observation and in the known fact that different ion pumping ATPases, namely Na+/K+-ATPase and Ca2+/Mg2+-ATPases, show little specificity towards inhibitors (11), we have studied the inhibition of HHIF on the Ca2+ pump of the plasma membrane of synaptosomes.

Keywords

Hydrolysis Filtration Lactate Pyruvate NADH 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Akerman KEO, Nicholls DG (1983) Ca2+ transport and the regulation of transmitter release in isolated nerve endings. Trends Biochem Sci 8: 63–64.CrossRefGoogle Scholar
  2. 2.
    Carilli CT, Berne M, Cantley LC Jr, Haupert GT, Jr. (1985) Hypothalamic factor inhibits the (Na/K)ATPase from the extracellular surface. J Biol. Chem 260, No. 2:1027–1031.PubMedGoogle Scholar
  3. 3.
    de Wardener HE, MacGregor GA (1980) Dahl’s hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure:its possible role in essential hypertension. Kidney Int 18: 1–9.PubMedCrossRefGoogle Scholar
  4. 4.
    García-Martín E, Gutiérrez-Merino C (1986) Local anesthetics inhibit the Ca2+,Mg2+-ATPase activity of rat brain synaptosomes. J Neurochem 47: 668–672.PubMedCrossRefGoogle Scholar
  5. 5.
    García-Martín E, Gutiérrez-Merino C (1990) Modulation of the Ca2+,Mg2+-ATPase activity of synaptosomal plasma membrane by the local anesthetics dibucaine and lidocaine. J Neurochem 54: 1238–1246.PubMedCrossRefGoogle Scholar
  6. 6.
    Gill DL, Grollman EF, Khon LD (1981) Calcium transport mechanisms in memebrane vesicles from guinea pig brain synaptosomes. J Biol Chem 256: 184–192.PubMedGoogle Scholar
  7. 7.
    Haddy FJ, Pamnani MB, Clough DL, Huot S (1982) Role of a humoral sodium-po-tasium pump inhibitor in experimental low renin hypertension. Life Sci 30:571–575.PubMedCrossRefGoogle Scholar
  8. 8.
    Illescas M, Ricote M, Mendez E, G-Robles R, Sancho J (1990) Complete purification of two identical Na(+)-pump inhibitors isolated from bovine hypothalamus and hypophysis. FEBS Lett 261: 436–440.PubMedCrossRefGoogle Scholar
  9. 9.
    Josephson L, Cantley LC Jr (1977) Isolation of a potent (Na+-K+)ATPase inhibitor from striated muscle. Biochemistry 16: 4572–4578.PubMedCrossRefGoogle Scholar
  10. 10.
    Montero A, Rodriguez-Barbero A, Ricote M, Sancho J, López-Novoa JM (1993) Effect of ouabain and hypothalamic, hypophysary inhibitory factor on rat mesangial cell proliferation. J Cardiovasc Pharmacol 22(Suppl.2):S35–S37.PubMedCrossRefGoogle Scholar
  11. 11.
    Pedersen PL, Carafoli E (1987) Ion motive ATPases.I.Ubiquity, properties, and significance to cell function. Trends Biochem Sci 12: 146–150.CrossRefGoogle Scholar
  12. 12.
    Sancho J, García-Martín E, García-Robles R, Santirso R, Villa E, Gutiérrez-Merino C, Ricote M (1993) Properties of the purified hypothalamic pituitary Na/K-ATPase inhibitor. J Cardiovas Pharmacol 22(Suppl.2): S32–S34.CrossRefGoogle Scholar

Copyright information

© Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1994

Authors and Affiliations

  • M. Ricote
    • 1
    • 2
  • E. Garcia
    • 1
    • 2
  • C. Gutierrez
    • 1
    • 2
  • J. Sancho
    • 1
    • 2
  1. 1.Serv. Endocrinología. Hosp.Ramón y CajalMadridSpain
  2. 2.Dept. Bioqufmica y Biología Molecular y Genética, Facultad de CienciasUNEXBadajozSpain

Personalised recommendations